Format

Send to

Choose Destination
AIDS Behav. 2017 Dec;21(12):3336-3345. doi: 10.1007/s10461-017-1969-1.

Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.

Author information

1
HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute, Columbia University, New York, NY, USA. ac72@cumc.columbia.edu.
2
Unit 15, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA. ac72@cumc.columbia.edu.
3
HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute, Columbia University, New York, NY, USA.
4
Department of Medicine, Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, CA, USA.
5
UCSF Center for Vulnerable Populations, Health Communications Research Program, Zuckerberg San Francisco General Hospital, San Francisco, CA, USA.
6
Department of Biostatistics, University of Washington, Seattle, WA, USA.
7
Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.
8
Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
9
Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
10
Thailand Ministry of Public Health - U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand.
11
Asociación Civil Impacta Salud y Educación, Lima, Peru.
12
U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.
13
San Francisco Department of Public Health, San Francisco, CA, USA.
14
The Fenway Institute, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA.
15
Department of Obstetrics and Gynecology, University of Puerto Rico School of Medicine, San Juan, PR, USA.
16
School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Abstract

Oral pre-exposure prophylaxis (PrEP) can prevent HIV transmission. Yet, some may prefer not to take systemic daily medication. MTN-017 was a 3-period, phase 2 safety and acceptability study of microbicide gel applied rectally either daily or before and after receptive anal intercourse (RAI), compared to daily oral tablet. At baseline, cisgender men and transgender women who reported RAI (N = 187) rated the daily oral regimen higher in overall liking, ease of use, and likelihood of future use than the gel regimens. After trying all three, 28% liked daily oral the least. Gel did not affect sexual enjoyment (88%) or improved it (7-8%). Most partners had no reaction to gel use. Ease of gel use improved significantly between the first and the last few times of daily use. A rectal gel used before and after RAI may constitute an attractive alternative to daily tablet. Experience with product use may increase acceptability.

KEYWORDS:

Acceptability; Gel; Microbicide; PrEP; Rectal

PMID:
29119473
PMCID:
PMC5856109
[Available on 2018-12-01]
DOI:
10.1007/s10461-017-1969-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center